Notably, pharmacological inhibition of glycolytic flux via non-metabolizable glucose analogue, 2-deoxy-glucose (2-DG) and GLUT1-specific inhibitor, WZB117, selectively suppresses tumour growth in SqCC, whereas ADC is significantly resistant to glycolytic inhibition. This evidence concerns the gene SLC2A1 and neoplasm.